HWN Suggests

Researchers Conclude: Cholinesterase Inhibitors Don’t Delay Alzheimer’s

Acetylcholinesterase inhibitors (donepezil, galantamine, and rivastigmine) represent one of only two classes of drugs approved for treatment of Alzheimer disease, the other being the glutamate receptor antagonist memantine. The former give a boost to a flagging cholinergic system by preventing degradation of released acetylcholine, and as such they temporarily improve cognition in patients with mild to moderate AD. However, they are generally thought not to prevent the inexorable neurodegeneration and associated neurologic decline.

read full article

Featured

  The hard truth about Alzheimer's drugs

Aricept, Exelon, and Razadyne do little to help most people and pose risks. It's true that Alzheimer's drugs have undergone extensive study. But the overall results are far less encouraging than the ads portray. Most people who take them don't experience a meaningful benefit. More than half experience side effects. And they're expensive,... And through it all, the thief continues unchecked—none of the drugs can reverse the disease.

 Cholinesterase inhibitors as Alzheimer's therapeutics (Review)

Currently, the available drugs for AD are predominantly cholinesterase inhibitors. However, the efficacy of these drugs is limited as they may cause adverse side effects and are not able to completely arrest the progression of the disease.

 Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease

Overall, the efficacy of the three ChE-Is available in the market is similar and the benefit of administration of these compounds is mild and may not be clinically significant.

 How Exactly Do Different Kinds of Alzheimer’s Medications Work?

These medications include galantamine (Razadyne), donepezil (Aricept), and rivastigmine (Exelon). They're FDA-approved to treat the symptoms of mild to moderate dementia symptoms associated with Alzheimer's disease, and they affect acetylcholine, a chemical that plays a role in muscle activity, attention, learning, and memory.

Articles of Interest

Mad in America

A 2006 Cochrane review of donepezil, galantamine, and rivastigmine didn’t pay attention to this problem and concluded that, “The three cholinesterase inhibitors are efficacious for mild to moderate Alzheimer’s disease.” Even without considering the unblinding problem, this conclusion was unwarranted. The improvement in cognitive function was 2.7 points, in the midrange of a 70-point scale. This is less than the 4 points the FDA considers the minimally relevant clinical change.

Acetylcholinesterase Inhibitors: Beneficial Effects on Comorbidities in Patients With Alzheimer’s Disease

We here report evidence from the literature that ACHEI treatment, prescribed for cognitive impairment, can reduce the load of medications in patients with AD by also addressing cardiovascular, gastrointestinal, and other comorbidities. Using one drug to address multiple symptoms can reduce costs and improve medication compliance.

Alzheimer's drugs a waste of money, says NHS study

Drugs for Alzheimer's disease, which pharmaceutical companies and campaigners have lobbied the government to provide to large numbers of elderly patients with dementia across the country at a cost of over £39m a year, have little effect on their memory and do not stop the distressing deterioration of their lives, according to an important study published today.

British Study Sees Scant Value In Alzheimer's Drug Aricept

The most widely prescribed drug for Alzheimer's disease, Aricept, does not delay the onset of disability or the need for a nursing home, British researchers are reporting today. The researchers say that the drug has ''disappointingly little overall benefit'' and is not cost-effective, and that better treatments are needed. Experts in the United States are already divided over the usefulness of Aricept and related drugs, and the study is unlikely to end the debate.

Cholinesterase Inhibitors Associated With Slower Cognitive Decline in Alzheimer’s

Cholinesterase inhibitors are a group of drugs recommended for the treatment of Alzheimer's disease, but their effects on cognition have been debated and few studies have investigated their long-term effects. A new study involving researchers from Karolinska Institutet in Sweden and published in the journal Neurology shows persisting cognitive benefits and reduced mortality for up to five years after diagnosis.

Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease

ChE inhibitors offer an evidence-based approach to delaying the symptomatic decline seen in patients with AD. All ChE inhibitors prevent the hydrolysis of ACh and have demonstrated efficacy, first in clinical trials and more recently in clinical practice. Although all these agents share a common mechanism of action, we know that the drugs differ pharmacologically. These differences can significantly affect the safety, tolerability, and efficacy profiles of each drug and may ultimately determine the success of treatment.

Common Alzheimer’s Medications Slow Cognitive Decline

Swedish researchers find that cholinesterase inhibitors provide cognitive benefits and reduce mortality for up to five years after an Alzheimer's diagnosis. One medication significantly reduced the risk of developing severe dementia.

Current Treatments for Alzheimer's Limited

Cholinesterase inhibitors are designed to prevent the breakdown of acetylcholine, a chemical messenger important for memory and other cognitive functions, and keep levels high even when the cells that produce it degenerate or die. Of this class of drugs, the most commonly prescribed are donepezil (Aricept); rivastigmine (Exelon) and galantamine (Reminyl). About half the people taking these drugs experience a modest improvement in memory and other thinking skills.

Drug treatments for Alzheimer’s disease: Cholinesterase inhibitors

The effect of these drugs varies for different people. Some will not notice any effect. Others may find that their symptoms improve slightly. And others will stay the same when they would have expected their symptoms to become gradually worse.

Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality

ChEIs are associated with cognitive benefits that are modest but persist over time and with reduced mortality risk, which could be explained partly by their cognitive effects. Galantamine was the only ChEI demonstrating a significant reduction in the risk of developing severe dementia.

Neuroprotective Effects of Cholinesterase Inhibitors: Current Scenario in Therapies for Alzheimer’s Disease and Future Perspectives

AD is considered a complex multifactorial disease. The use of cholinesterase inhibitors (donepezil, rivastigmine, galantamine) is currently the main treatment modality. Several in vitro and in vivo studies have shown that traditional ChEI is provided with cholinergic activities as well as activity against various AD molecular targets, but their effects in reducing AD progression are still limited.

The Race for a Pill To Save Memory

Three drugs being prescribed for Alzheimer's disease -- donepezil (Aricept), galantamine (Reminyl) and rivastigmine (Exelon) -- have been shown to delay somewhat the loss of mental abilities in people with the illness. So has the drug memantine, which has been used for years in Europe but has not been approved in the United States. Some experts also say that performing mental exercises and adding fish oil to the diet can delay memory decline.

Resources

StatPearls

Cholinesterase inhibitors function to decrease the breakdown of acetylcholine. They SEe use in the treatment of Alzheimer and dementia symptoms...